AskGene Pharma is led by a team of world-class scientists with extensive experience in the discovery and development of novel biologic therapeutics.
Jian-Feng “Jeff” Lu, Ph.D.
President and CEO
Dr. Jian-Feng Lu has been President and Chief Executive Officer of AskGene Pharma since its inception. He has more than 25 years’ experience in clinical pharmacology, including more than 12 years in PK/PD and drug development across various therapeutic areas at Genentech and Amgen. Dr. Lu’s previous posts included Pharmacometrician at Genentech and progressed to a Scientific Director at Amgen. During his tenure, he participated in the first BLA filing of Avastin and the first NDA filing of Tarceva. Additionally, Dr. Lu was responsible for PK/PD assessment, dose selection, and study design for many projects from pre-clinical stage to phase I, II and III, including biologics, small molecule, and antibody-drug conjugate programs.
Dr. Lu received his Ph.D. in Pharmaceutics from China Pharmaceutical University and completed his post-doctoral training at the University of California San Francisco (UCSF). Dr. Lu is a guest professor at Jiangnan University and was invited to draft the biosimilar guidance for China’s State Food and Drug Administration (CFDA).
Yuefeng Lu, Ph.D.
Chief Scientific Officer
Dr. Yuefeng Lu joined AskGene Pharma in June 2013. From 2002 to 2013, Dr. Lu was Principal Scientist of Process Development at Amgen, where he led process development, pivotal and commercial tech transfer, and manufacturing support for several recombinant antibody and fusion protein projects. Dr. Lu has more than 20 years of biotech industrial experience. Prior to Amgen, he worked in process development and drug discovery at Protein Design Labs, GeneTrol, and Pan Pacific Pharmaceuticals.
Dr. Lu received his Ph.D. in Biochemistry from University of Minnesota, Twin Cities, and completed his post-doctoral training at Stanford University. Dr. Lu is the inventor or co-inventor of more than a dozen of issued and pending patents.
Ray Chuang, Ph.D.
Senior Director Cell Line Development
Dr. Chuang joined AskGene Pharma in September 2018. He has more than 16 years’ industrial experience in research discovery and cell line development in both the diagnostic and pharmaceutical industries. Previously, he was R&D Manager of Cell Biology at Thermo Fisher Scientific’s TDX division. He also worked at Shire Pharmaceuticals (acquired by Takeda in 2019) and Genesun Biopharmaceuticals as Associate Director of Cell Line Development, and prior to that was an R&D scientist at Multispan. He completed his postdoctoral fellowship at Johnson & Johnson Pharmaceuticals.
Dr. Chuang received his PhD in Cell & Development Biology from the University of Michigan at Ann Arbor and his postdoctoral training at Salk Institute for Biological Studies.
Stone Shi, Ph.D.
Senior Director of Purification/Analytical/Formulation
Dr. Stone Shi joined AskGene Pharma in January 2021, bringing 22 years of combined industry experience. Previously, Dr. Shi served as Principal Scientist at Amgen, where he held a number of leadership roles, including leader of mass spec group, founding leader of discovery molecule assessment (DiscMA) group, discovery project co-lead (BioRep), process development attribute science team lead (ASTL) for a number of projects successfully achieving IND, and global molecule assessment co-coordinator. Prior to Amgen, Dr. Shi served at Pfizer and GSK
Dr. Shi received his bachelor’s and master’s degree in Chemistry from Tsinghua University, and a Ph.D. degree in Analytical Chemistry from Florida State University and the National High Magnetic Field Laboratory. He has published more than 20 research papers, and is the co-inventor of two issued patents.
Ming Li, Ph.D.
Senior Director of Quality and Compliance
Dr. Li joined AskGene Pharma in September of 2016. She has more than 20 years’ experience in product development and manufacturing support for recombinant and plasma therapeutic at various biotech companies. Prior to AskGene, she was a senior manager at Baxter and later at Shire, where she was responsible for analytical development to support product and process development, manufacturing investigations, and quality control. Previously, she worked on analytical development for protein and antibody therapeutics at Amgen.
Dr. Li received her Ph.D. in Biochemistry and Biophysics from the University of Minnesota and completed her post-doctoral training at California Institute of Technology (Caltech). Dr. Li is the author of more than 20 publications in peer-reviewed journals. She was also a speaker on analytical development at various national conferences.